# Case Report: Atypical extensive orbitofacial tuberculosis extending to the skull base and cavernous sinus revealed major histocompatibility complex class II deficiency in an 11-year-old girl

**Authors:** Sameh Mezri, Ameni Amri, Sonia Essghaier, Karima Tlili, Maroua Rabhi, Mahdi Marmouri, Hager Barakizou

PMC · DOI: 10.3389/fped.2025.1663784 · Frontiers in Pediatrics · 2025-11-04

## TL;DR

An 11-year-old girl with a rare form of tuberculosis and an immune deficiency was diagnosed and treated, highlighting the need to consider tuberculosis in unusual infections.

## Contribution

This is the first reported case of cavernous sinus tuberculosis in a child with MHC class II deficiency.

## Key findings

- Cavernous sinus tuberculosis can present with severe headaches and orbital swelling in children.
- MHC class II deficiency can manifest as severe or recurrent infections, including tuberculosis.
- Anti-tuberculosis therapy combined with immunoglobulin replacement improved clinical outcomes.

## Abstract

Cavernous sinus tuberculosis is an extremely rare manifestation of central nervous system tuberculosis in children, with only two cases reported worldwide. It can mimic malignancy or other inflammatory conditions. Its occurrence in children with primary immunodeficiency, particularly major histocompatibility complex (MHC) class II deficiency, has not yet been described.

We report an 11-year-old girl with a history of recurrent infections and chronic otitis media. She presented with right orbital swelling, severe headaches, and exophthalmos. Imaging revealed an extensive mass in the sinonasal and orbital regions, extending to the skull base and cavernous sinus. A computed tomography-guided biopsy and histopathology, supported by PCR testing for Mycobacterium tuberculosis, confirmed extensive orbital and cervicofacial tuberculosis. An immunological evaluation and genetic analysis revealed familial MHC class II deficiency. The patient received anti-tuberculosis therapy [isoniazid, rifampin, pyrazinamide, and ethambutol (HRZE) followed by isoniazid and rifampin (HR)], leading to clinical and radiological improvement. She continues with intravenous immunoglobulin replacement therapy every 21 days while awaiting a bone marrow transplantation.

This case highlights the importance of considering tuberculosis in atypical cavernous sinus lesions in children, especially in endemic regions. Severe or unusual infections should prompt evaluation for underlying immunodeficiency.

## Linked entities

- **Chemicals:** isoniazid (PubChem CID 3767), rifampin (PubChem CID 135398735), pyrazinamide (PubChem CID 1046), ethambutol (PubChem CID 14052)
- **Diseases:** tuberculosis (MONDO:0018076), chronic otitis media (MONDO:0021204)

## Full-text entities

- **Diseases:** exophthalmos (MESH:D005094), central nervous system tuberculosis (MESH:D020306), headaches (MESH:D006261), primary immunodeficiency (MESH:D000081207), orbital swelling (MESH:D009916), infections (MESH:D007239), chronic otitis media (MESH:D010033), malignancy (MESH:D009369), cavernous sinus lesions (MESH:D020226), inflammatory (MESH:D007249), Cavernous sinus tuberculosis (MESH:D014376), MHC class II deficiency (MESH:D008312), immunodeficiency (MESH:D007153)
- **Chemicals:** HRZE (-), pyrazinamide (MESH:D011718), rifampin (MESH:D012293), isoniazid (MESH:D007538), ethambutol (MESH:D004977)
- **Species:** Mycobacterium tuberculosis (species) [taxon 1773], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12623361/full.md

## Figures

4 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12623361/full.md

## References

20 references — full list in the complete paper: https://tomesphere.com/paper/PMC12623361/full.md

---
Source: https://tomesphere.com/paper/PMC12623361